Gut Microbiome and Microbiome-Derived Metabolites in Patients with End-Stage Kidney Disease
International Journal of Molecular Sciences · 14.07.2023 · 24 (14) · 11456
DOI: 10.3390/ijms241411456 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 14.07.2023. Verfasst von Takeo Koshida und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Faculty of Medicine, Juntendo University, Bunkyo-ku 113-8421, Tokyo, Japan. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Diabetes Mellitus, Type 2, Kidney Failure, Chronic, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kowa (Japan), Tokyo Diabetic Nephropathy Seminar (TDNS) of the Kowa Company.
Abstract (Originalsprache)
The composition of the gut microbiome is altered in patients with chronic kidney disease (CKD). Dysbiosis leads to decreased levels of stool organic acids (OAs) and systemic inflammation, followed by accumulation of uremic toxins (UTs) and the development of end-stage kidney disease (ESKD). We assessed the relationship between the microbiome and UT levels or the development of ESKD by comparing patients undergoing hemodialysis (HD) and those with normal renal function (NRF). This cross-sectional study recruited 41 patients undergoing HD and 38 sex- and age-matched patients with NRF, and gut microbiome, levels of plasma UTs, inflammatory markers, and stool OAs were compared. The indices of beta-diversity differed significantly between patients with NRF and those undergoing HD, and between patients undergoing HD with and without type 2 diabetes. The levels of stool total OA, inflammatory markers, and UTs differed significantly between the patients with NRF and those undergoing HD. The combined main effects of type 2 diabetes and kidney function status were accumulation of indoxyl sulfate and p-cresyl sulfate. The relative abundances of Negativicutes and Megamonas were associated with development of ESKD and with the levels of UTs, even after adjustment for factors associated with the progression of ESKD. The present study indicates that the gut environment differs between patients with NRF and those undergoing HD and between patients undergoing HD with and without type 2 diabetes. Moreover, ESKD patients with diabetes accumulate more UTs derived from the gut microbiome, which might be associated with cardio-renal diseases and poor prognosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nephrology, Faculty of Medicine, Juntendo University, Bunkyo-ku 113-8421, Tokyo, Japan.
- Yakult Central Institute, Yakult Honsha Co., Ltd., Kunitachi-shi 186-0012, Tokyo, Japan.
- Department of Internal Medicine, Saiyu Soka Hospital, Soka-shi 340-0041, Saitama, Japan.
- Probiotics Research Laboratory, Graduate School of Medicine, Juntendo University, Bunkyo-ku 113-8421, Tokyo, Japan.
ORCID-Profile: Takeo Koshida, Tomohito Gohda, Takuya Sugimoto, Rin Asao, Maki Murakoshi
Förderung
- Kowa (Japan)
- Tokyo Diabetic Nephropathy Seminar (TDNS) of the Kowa Company
Zitieren
APA
Koshida, T., Gohda, T., Sugimoto, T., Asahara, T., Asao, R., Ohsawa, I., Gotoh, H., Murakoshi, M., Suzuki, Y., & Yamashiro, Y. (2023). Gut Microbiome and Microbiome-Derived Metabolites in Patients with End-Stage Kidney Disease. International Journal of Molecular Sciences, 24(14), 11456. https://doi.org/10.3390/ijms241411456
Vancouver
Koshida T, Gohda T, Sugimoto T, Asahara T, Asao R, Ohsawa I, et al. Gut Microbiome and Microbiome-Derived Metabolites in Patients with End-Stage Kidney Disease. International Journal of Molecular Sciences. 2023;24(14):11456. doi:10.3390/ijms241411456
BibTeX
@article{Koshida2023,
author = {Koshida, Takeo and Gohda, Tomohito and Sugimoto, Takuya and Asahara, Takashi and Asao, Rin and Ohsawa, Isao and Gotoh, Hiromichi and Murakoshi, Maki and Suzuki, Yusuke and Yamashiro, Yuichiro},
title = {Gut Microbiome and Microbiome-Derived Metabolites in Patients with End-Stage Kidney Disease},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {14},
pages = {11456},
doi = {10.3390/ijms241411456}
}
EUVIMED